English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/168852
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer

AuthorsAlcaraz-Sanabria, Ana; Nieto-Jiménez, Cristina; Corrales-Sánchez, Verónica; Serrano-Oviedo, Leticia; Andrés-Pretel, Fernando; Montero, Juan Carlos CSIC ORCID; Burgos, Miguel; Llopis, Juan; Galán-Moya, Eva María; Pandiella, Atanasio CSIC ORCID CVN ; Ocaña, Alberto
Issue Date2017
PublisherAmerican Association for Cancer Research
CitationMolecular Cancer Therapeutics 16(11): 2552-2562 (2017)
AbstractOvarian cancer is characterized by frequent mutations at TP53. These tumors also harbor germline mutations at homologous recombination repair genes, so they rely on DNA-damage checkpoint proteins, like the checkpoint kinase 1 (CHEK1) to induce G arrest. In our study, by using an in silico approach, we identified a synthetic lethality interaction between CHEK1 and mitotic aurora kinase A (AURKA) inhibitors. Gene expression analyses were used for the identification of relevant biological functions. OVCAR3, OVCAR8, IGROV1, and SKOV3 were used for proliferation studies. Alisertib was tested as AURKA inhibitor and LY2603618 as CHEK1 inhibitor. Analyses of cell cycle and intracellular mediators were performed by flow cytometry and Western blot analysis. Impact on stem cell properties was evaluated by flow cytometry analysis of surface markers and sphere formation assays. Gene expression analyses followed by functional annotation identified a series of deregulated genes that belonged to cell cycle, including AURKA/B, TTK kinase, and CHEK1. AURKA and CHEK1 were amplified in 8.7% and 3.9% of ovarian cancers, respectively. AURKA and CHEK1 inhibitors showed a synergistic interaction in different cellular models. Combination of alisertib and LY2603618 triggered apoptosis, reduced the stem cell population, and increased the effect of taxanes and platinum compounds. Finally, expression of AURKA and CHEK1 was linked with detrimental outcome in patients. Our data describe a synthetic lethality interaction between CHEK1 and AURKA inhibitors with potential translation to the clinical setting.
Publisher version (URL)https://doi.org/10.1158/1535-7163.MCT-17-0223
URIhttp://hdl.handle.net/10261/168852
DOIhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0223
Identifiersdoi: 10.1158/1535-7163.MCT-17-0223
e-issn: 1538-8514
issn: 1535-7163
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
syntcanc.pdf1,92 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.